Protein O‐glycosylation in the Bacteroidota phylum
FEBS Open Bio, EarlyView.Species of the Bacteroidota phylum exhibit a unique O‐glycosylation system. It modifies noncytoplasmic proteins on a specific amino acid motif with a shared glycan core but a species‐specific outer glycan. A locus of multiple glycosyltransferases responsible for the synthesis of the outer glycan has been identified.
Lonneke Hoffmanns +2 more
wiley +1 more source
Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review [PDF]
Iranian Journal of Basic Medical Sciences, 2018 Objective(s): Production of effective tuberculosis (TB) vaccine is necessity. However, the development of new subunit vaccines is faced with concerns about their weak immunogenicity. To overcome such problems, polymers-based vaccine delivery systems have
Farzad Khademi +3 more
doaj +1 more source
Novel expression of Haemonchus contortus vaccine candidate aminopeptidase H11 using the free-living nematode Caenorhabditis elegans [PDF]
, 2013 With the problem of parasitic nematode drug resistance increasing, vaccine development offers an alternative sustainable control approach. For some parasitic nematodes, native extracts enriched for specific proteins are highly protective.
Antonopoulos, A. +8 more
core +3 more sources
Arthritis Care &Research, Accepted Article.Objective This systematic review aimed to assess the diagnostic accuracy of algorithms used to identify rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) in electronic health records (EHRs). Methods We searched MEDLINE, Embase, and CENTRAL databases and included studies that validated case definitions against a reference standard such ...
Constanza Saka‐Herrán +10 more
wiley +1 more source
Advancing mRNA technologies for therapies and vaccines: An African context
Frontiers in Immunology, 2022 Synthetic mRNA technologies represent a versatile platform that can be used to develop advanced drug products. The remarkable speed with which vaccine development programs designed and manufactured safe and effective COVID-19 vaccines has rekindled ...
Dylan Kairuz +4 more
doaj +1 more source
Biochemical prevention and treatment of viral infections – A new paradigm in medicine for infectious diseases [PDF]
, 2004 For two centuries, vaccination has been the dominating approach to develop prophylaxis against viral infections through immunological prevention. However, vaccines are not always possible to make, are ineffective for many viral infections, and also carry
Fang, Fang, Le Calvez, Hervé, Yu, Mang
core +3 more sources
The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses [PDF]
, 2020 We are proposing the use of pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses. The designed strategy represents a potential treatment to reduce the overall viral load in the lungs and to help the immune system to successfully stave
Feliciello, Isidoro, Procino, Alfredo
core +1 more source
Next generation self-replicating RNA vectors for vaccines and immunotherapies
Cancer Gene Therapy, 2022 RNA technology has recently come to the forefront of innovative medicines and is being explored for a wide range of therapies, including prophylactic and therapeutic vaccines, biotherapeutic protein expression and gene therapy.
Parinaz Aliahmad +3 more
semanticscholar +1 more source
Versatile Cell Penetrating Peptide for Multimodal CRISPR Gene Editing in Primary Stem Cells
Advanced Functional Materials, EarlyView.CRISPR machinery in diverse molecular formats (DNA, RNA, and ribonucleic protein) is complexed into nanoparticles with the cell‐friendly arginine‐alanine‐leucine‐alanine (RALA) cell‐penetrating peptide. Nanoparticles are delivered to primary mesenchymal stem cells ex vivo or locally in vivo to facilitate multimodal CRISPR gene editing. This RALA‐CRISPR
Joshua P. Graham +9 more
wiley +1 more source
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines
Vaccines, 2016 Aberrantly glycosylated mucin 1 (MUC1) is a recognized tumor-specific antigen on epithelial cell tumors. A wide variety of MUC1 glycopeptide anti-cancer vaccines have been formulated by many research groups.
Md Kamal Hossain, Katherine A. Wall
doaj +1 more source